

Access to Vaccines Index

Developing Countries Vaccine Manufacturers Network webinar

Jayasree K. Iyer, Executive Director

Catherine Gray, Project Lead

8 March 2016

**5 billion people
have access to medicine
2 billion to go**

Availability

Accessibility

Affordability

Quality/
Acceptability

The Foundation

access to
medicine
FOUNDATION

- Research on, and incentives for, pharmaceutical companies and access to medicine
- Fully independent from pharmaceutical companies
- Multi-stakeholder approach
- 2016: 5th Access to Medicine Index
- 2017: 1st Access to Vaccines Index



Ministry of Foreign Affairs
of the Netherlands



Department
for International
Development

BILL & MELINDA
GATES *foundation*



Our mechanisms for change

Build consensus

on what to expect from the industry and where incentives and disincentives exist.



Stimulate a “race to do well”

in key access-to-medicine areas, by creating competition on targets and topics.



Diffuse best practices

to share information and new insights into the best approaches for driving change.




What we do

access to
medicine
FOUNDATION

Access to Medicine Index



Thematic studies



Access to Vaccines Index



Advancing the debate




What we do

access to
medicine
FOUNDATION


Access to Medicine Index




Thematic studies



Access to Vaccines Index




Advancing the debate



Access to Medicine Index in top 3 credible ratings



Experts deem the CDP, Dow Jones Sustainability Index and Access to Medicine Index as the three most credible ratings.



Question

How credible do you find the following ratings and rankings to be?

Please use the 5-point scale provided, where 1 is "not at all credible" and 5 is "very credible," or choose "not familiar."

The 2013 Ratings Survey

Polling the Experts

A GlobeScan/SustainAbility Survey

Funders



"The companies at the top of the Index want to do more. The ones at the bottom see that and push forward on it."


Bill Gates

Pharma Companies



"The Index challenges us to think harder about how we drive innovation and enable access to our products."

Sir Andrew Witty, GSK CEO



Global Health



"The Index is a very important project. What gets measured, gets done."

Dr Margaret Chan

Media



"While progress is uneven, many drug makers are, by and large, making headway. In fact, access is increasingly seen as a necessary business issue."

Wall Street Journal

Investors



"We are increasingly reviewing corporate approaches to access to medicine as a key strategic consideration."

53 Signatory Investors

Independent evaluation of Access to Medicine Index shows:

access to
medicine
FOUNDATION

Main findings:

1. Framework is holistic, “golden standard”
2. Companies use report to learn and develop strategies
3. More can be done with governments and investors

54 investors: US\$5.31 trillion


access to
medicine
FOUNDATION




What we do

access to
medicine
FOUNDATION

Access to Medicine Index




Thematic studies



Access to Vaccines Index



Advancing the debate



Thematic studies 2015

access to
medicine
FOUNDATION

April 2015

Improving Maternal Health



- Pharma's contribution to MDG 5
- UN Foundation – Every Woman, Every Child
- 2 new commitments from companies

September 2015

Vaccine Pipeline Analysis



- Pipeline study for high-burden diseases
- Evidence of access provisions for future vaccines

November 2015

On Hepatitis-C



- Access to Hepatitis C treatments
- Landscape study – policy recommendations
- Publication in WHO Bulletin


What we do

access to
medicine
FOUNDATION


Access to Medicine Index



Thematic studies




Access to Vaccines Index



Advancing the debate




access to medicine FOUNDATION




What we do

access to
medicine
FOUNDATION

Access to Medicine Index



Thematic studies



Access to Vaccines Index



Advancing the debate



DCVMN: Contributing to access

access to
medicine
FOUNDATION



Access to Vaccines Index: A new catalyst for action

- What is the role for vaccine companies in improving access?
- Baseline of companies' access efforts, e.g.:
 - *R&D to fill product gaps*
 - *Registration in high-need countries*
 - *Collaboration to align supply and demand*
 - *Addressing supply chain issues*
- Track progress
- Identify incentives and barriers for the industry
- Share best practices

Building the methodology in 2015

access to
medicine
FOUNDATION

Feasibility &
landscaping





Founding
principles




Building
the metrics



Methodology



Methodology: Access to Vaccines Index



Scopes

- Preventive vaccines
- 69 diseases
- 107 countries
- 9 companies

Disease scope

WHO position

- Routine immunization schedules
- R&D priority

Stakeholder recommendations

- Maternal immunisation
- Emerging infectious diseases
- Diarrhoeal diseases
- Lower respiratory infections
- Neglected tropical diseases

69 diseases

With existing vaccines


| |
|--|
| Cholera |
| Diphtheria |
| <i>Haemophilus influenzae</i> type B (Hib) |
| Human papillomavirus (HPV) |
| Japanese encephalitis |
| Malaria* |
| Measles |
| Meningococcal disease |
| Mumps |
| Pandemic influenza |
| Pertussis |
| Plague (<i>Yersinia pestis</i>) |
| Pneumococcal disease |
| Polio |
| Rabies |
| Rotavirus |
| Rubella |
| Seasonal influenza |
| Tetanus |
| Tick-borne encephalitis |
| Tuberculosis |
| Typhoid |
| Varicella |
| Viral hepatitis (A, B, C, E)** |
| Yellow fever |

Without existing vaccines

| | |
|------------------------------------|--|
| Adenovirus | <i>Klebsiella pneumoniae</i> |
| Amoebiasis | Lassa fever |
| Balantidiasis | Leishmaniasis |
| Buruli Ulcer | Leprosy |
| Campylobacter enteritis | Lymphatic filariasis |
| Chagas disease | Marburg (haemorrhagic) virus |
| Chikungunya | Onchocerciasis |
| <i>Clostridium difficile</i> | Parainfluenza |
| Cryptosporidiosis | <i>Pneumocystis jiroveci</i> |
| Cytomegalovirus (CMV) | Respiratory Syncytial Virus (RSV) |
| Dengue | Schistosomiasis |
| Dracunculiasis | Severe Acute Respiratory Syndr. (SARS) |
| Ebolavirus | Shigellosis |
| Echinococcosis | Soil-transmitted helminthiasis |
| Enterovirus 71 | <i>Staphylococcus aureus</i> * |
| <i>Escherichia coli</i> infections | Taeniasis/cysticercosis |
| Food-borne trematodiasis | Trachoma |
| Giardiasis | Yaws |
| Group B streptococcus | <i>Yersinia enterocolitica</i> |
| Hantavirus pneumonia | |
| Human African trypanosomiasis | |
| Human Immunodeficiency virus (HIV) | |
| Human metapneumovirus | |
| Human monkeypox | |
| Isosporiasis | |

107 countries

access to
medicine
FOUNDATION



Legend: Basis for inclusion

- On Gavi support
- Transitioning from Gavi support
- Not on Gavi support
- Outside country scope

9 companies

List of companies included in the 2017 Access to Vaccines Index – 9 companies

| Company | Country | Total revenue 2014 (bn USD) | Vaccine revenue 2014 (bn USD) |
|--------------------------------|---------|--------------------------------|----------------------------------|
| AstraZeneca plc | GBR | 26.1 | 0.295 |
| Daiichi Sankyo Co. Ltd. | JPN | 7.6 | n/a |
| GlaxoSmithKline plc | GBR | 37.9 | 5.26 |
| Johnson & Johnson | USA | 74.3 | n/a |
| Merck & Co. Inc. | USA | 42.2 | 6.25 |
| Pfizer Inc. | USA | 49.6 | 4.48 |
| Sanofi | FRA | 43.1 | 5.85 |
| Serum Institute of India Ltd. | IND | n/a | n/a |
| Takeda Pharmaceutical Co. Ltd. | JPN | 14.8 | 0.315 |

Research Areas

access to
medicine
FOUNDATION

R&D



Affordability



Manufacturing & Supply



A Research & Development

access to
medicine
FOUNDATION



A.1 R&D investments

A.2 R&D projects – vaccines

A.3 R&D projects – technologies

A.4 Facilitating access

B Affordability

access to
medicine
FOUNDATION



B.1 Needs-based pricing

B.2 Pricing transparency

B.3 Registration

C Manufacturing & Supply

access to
medicine
FOUNDATION



- C.1** Overcoming local barriers
- C.2** Ensuring rational use
- C.3** Responding to shortages
- C.4** Collaboration to align supply and demand
- C.5** Supporting vaccine security
- C.6** Increasing global manufacturing capacity

Questions?

Thank you

jiyer@atmindex.org
cgray@atmindex.org

www.atmindex.org

Data points – general

- Vaccines revenues
- Number of vaccine dosages sold annually
- Examples of response to market incentives
- Examples of market disincentives
- Vaccine R&D expenditures
- R&D projects – technologies
- Vaccine pricing strategy
- Public disclosure pricing strategy and price points
- Policy for filing for registration in Index Countries
- Strategy for responding to stock-outs
- Policy for engaging with purchasers and market shapers
- Policy for considering global health needs
- Examples of assisting manufacturers in Index Countries

Data points – product-specific

Marketed vaccines:

- Patent information
- Registration in Index Countries
- Adaptations to vaccines
- Adaptations to vaccine packaging and brochures

Pipeline vaccines:

- Phase of development
- Type of development (adaptive/innovative)
- Partnership information
- Access provisions